Andrew Gengos, President and CEO at ImmunoCellular Therapeutics, Ltd. (IMUC), bought 27,000 shares at $0.72 ($19K) on 2013-12-18, disclosed to the SEC on 2013-12-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| ATHA | SELL | 2024-09-05 | $725 | — | Filing → |
| ATHA | SELL | 2024-02-16 | $4K | — | Filing → |
| ATHA | SELL | 2024-01-08 | $4K | — | Filing → |